Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc has demonstrated strong growth metrics, with a 19% year-over-year revenue increase over the first nine months of the year, driven by a balanced combination of 9% growth in average selling prices (ASPs) and 8% growth in testing volumes. The company's average revenue per sales territory has significantly improved to approximately $430,000 in Q3, up from $285,000 two years prior, and plans to expand its territory count by five in the current year indicate a strategic focus on driving volume growth. With a 38% year-over-year increase in top-line revenue in Q3 and ongoing improvements in commercial operations, Exagen is on track to reach its long-term ASP target of $500/test by the second half of 2027.

Exagen Inc's outlook is negatively impacted by a lowered growth forecast for 2026 and delayed positive free cash flow, which have subsequently affected revenue estimates and margin expansion. The company's stock has experienced a significant decline of over 60% since the release of its third-quarter results, attributed to the loss of a direct bill account that represented 2% of volume. Furthermore, Exagen’s trading multiples are concerning, as it currently trades at a lower EV/revenue multiple compared to historical peers, indicating potential undervaluation amidst the financial challenges it faces.